Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764448 · ClinicalTrials.gov registry record · Phase 2
A Study of Belcesiran in Patients With AATLD
A Phase 2 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04764448 is a Phase 2 study that was terminated before completion, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 16 participants.
The verdict
NCT04764448, a Phase 2 study, was terminated before completion, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD). The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.
Interventions
- OTHER Placebo
- DRUG Belcesiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764448
The ClinicalTrials.gov registry entry for NCT04764448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04764448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764448 about?
NCT04764448 is a clinical study titled "A Study of Belcesiran in Patients With AATLD". This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD). The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be en...
What is the current status of trial NCT04764448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-02-12. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT04764448?
The interventions under investigation include: Placebo (OTHER), Belcesiran (DRUG).
Who is sponsoring clinical trial NCT04764448?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.